From "Can Percent Free Prostate-Specific Antigen Reduce the Need for Prostate Biopsy?" Effective Clinical Practice, November/December 1999. 2:266-271.
Figure 5. With use of a PSA cutoff of 25% (thin line), 13% of patients with benign disease would be spared biopsy and 97% of patients with cancer would be identified.>